ea0073aep305 | Diabetes, Obesity, Metabolism and Nutrition | ECE2021
Bostoganashvili Nestan
, Kvanchakhadze Rusudan
, Mikadze Ketevan
, Panchulidze Manoni
BackgroundIn Georgia, significantly huge number of patients with Diabetes Mellitus Type 2 (DMT2) suffer from cardiovascular diseases (CVD) and obesity. Since, dyslipidemia is one of major factors, leading to cardiovascular (CV) mortality, it is crucial to investigate the effects of relatively novel hypoglycemic agents- Sodium Glucose Cotransporter 2 (SGLT2) inhibitors (Dapagliflozin) or Glucagon like peptide 1 (GLP-1) agonists (Liraglutide) on lipid prof...